Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes

Heart

Volumn 103, Issue 21, 2017, Pages 1687-1695

  Matuleviciene Anängen, Viktorija ^a,g   Rosengren, Annika ^a   Svensson, Ann Marie ^b   Pivodic, Aldina ^c   Gudbjörnsdottir, Soffia ^a   Wedel, Hans ^d   Kosiborod, Mikhail ^e   Haraldsson, Börje ^a   Lind, Marcus ^a,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Center of Registers in Region Vastra Götaland   (Sweden)

^c Statistiska Konsultgruppen   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f NU Hospital Organization   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

blood glucose; coronary disease; diabetes complications; diabetes mellitus; myocardial infarction; type1

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEX; SEX DIFFERENCE; SWEDISH CITIZEN; ADOLESCENT; AGED; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; REGISTER; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85031328445     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-311050     Document Type: Article

References (30)

1. Hanås R. Typ 1 diabetes hos barn, ungdomar och unga vuxna: hur du blir expert på din egen diabetes. Beta Med 2010.
2. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-82.
3. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313:37-44.
4. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-5.
5. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006;49:660-6.
6. Diabetes Control and Complications Trial (DCCT (2016). "Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year followup". Diabetes care 2016;39.5:686-93.
7. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1):S14-80.
8. Eliasson B, Gudbjörnsdottir S. Diabetes care-improvement through measurement. Diabetes Res Clin Pract 2014;106(Suppl 2)91-4.
9. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015;373:1720-32.
10. Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011;378:140-6.
11. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 2010;33:1640-6.
12. Wettermark B, Hammar N, Fored CM, et al. The New Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
14. Lind M, Odén A, Fahlén M, et al. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes Metab Syndr 2008;2:282-93.
15. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
16. Huxley RR, Peters SAE, Mishra GD, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol 2015;3:198-206.
17. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease. Circulation 2014;130:1110-30.
18. Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the UK: a cohort study using the general practice research database. Diabetes Care 2006;29:798-804.
19. Ortega E, Amor AJ, Rojo-Martínez G, et al. Cardiovascular disease in patients with type 1 and type 2 diabetes in Spain. Medicina Clínica 2015;145:233-8.
20. Schutta MH. Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr 2007;2:124-30.
21. Vergès B. Lipid disorders in type 1 diabetes. Diabetes Metab 2009;35:353-60.
22. Lachin JM, Orchard TJ, Nathan DM, et al. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:39-43.
23. Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8.
24. Shankar A, et al. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007;166:393-402.
25. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38.
26. Prince CT, Becker DJ, Costacou T, et al. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 2007;50:2280-8.
27. Teleb M, Popp Switzer M, Elhanafi S, et al. Glycemic control and excess cardiovascular mortality in type 1 diabetes. Curr Cardiol Rep 2016;18:1-5.
28. Nyström T, Holzmann MJ, Eliasson B, et al. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass Grafting. J Am Coll Cardiol 2015;66:535-43.
29. National Board of Health and Welfare. Registeruppgifter om tobaksrökningens skadeverkningar: a 2014 report by the National Board of Health and Welfare. 2014 https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19371/2014-3-4.pdf (accessed 17 May 2017).
30. Statistics Sweden. Use of alcohol and tobacco. Living Conditions, Report no 114 http://www.scb.se/statistik/-publikationer/LE0101-2004I05-BR-LE114SA0701.pdf (accessed 17 May 2017).